Velvet Therapeutics
Velvet discloses amino-acid nanoparticles and minicircle DNA for in vivo CAR delivery to multiple immune-cell types. The accessible primary page does not specify a T-cell program or clinical stage; it is retained as an adjacent CAR platform rather than counted as a confirmed CAR-T developer.
Corporate information
- Company entity
- Velvet Therapeutics
- Headquarters / principal office
- No verified public location identified
- Founded
- Not verified
- Ownership / capital status
- Not verifiedNot verified
- Official corporate reference
- https://www.velvettherapeutics.com/ ↗
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
Velvet discloses amino-acid nanoparticles and minicircle DNA for in vivo CAR delivery to multiple immune-cell types. The accessible primary page does not specify a T-cell program or clinical stage; it is retained as an adjacent CAR platform rather than counted as a confirmed CAR-T developer.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.